Greenland Mines Ltd (GRML): Operating Income

Annual figures by period end, from SEC filings.

-$7.15M
Year ended 2025-12-31
-$18.67M
Trailing 12 months to 2026-06-30
2022-12-31: -$657.0K2023-12-31: -$631.3K2024-12-31: -$5.54M2025-12-31: -$7.15M-$7.15M
2022-12-31 Operating Income (USD) 2025-12-31
Period endedOperating IncomeChange YoYSource filing
2025-12-31-$7.15Mn/m2026-08-14, From 2025-01-01
2024-12-31-$5.54Mn/m2026-08-14, From 2024-01-01
2023-12-31-$631.3Kn/m2025-03-31, From 2023-01-01
2022-12-31-$657.0Kn/a2024-04-17, From 2022-01-01

Operating Income at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating IncomeChange YoY
Greenland Mines Ltd (GRML)2025-12-31-$7.15Mn/m
Dyadic International Inc (DYAI)2025-12-31-$7.19Mn/m
Calidi Biotherapeutics, Inc. (CLDI)2025-12-31-$20.24Mn/m
Scinai Immunotherapeutics Ltd. (SCNI)2025-12-31-$7.54Mn/m
Creative Medical Technology Holdings, Inc. (CELZ)2025-12-31-$6.14Mn/m
VivoSim Labs, Inc. (VIVS)2026-03-31-$11.49Mn/m
Silexion Therapeutics Corp (SLXN)2025-12-31-$11.63Mn/m
BioAtla, Inc. (BCAB)2025-12-31-$59.30Mn/m
Intensity Therapeutics, Inc. (INTS)2025-12-31-$11.97Mn/m

Compare GRML, DYAI, CLDI, SCNI side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗